Zongli ZHENG, PhD

Co-Founder and Chairman

Prof. Zheng is currently an Associate Professor in the Department of Biomedical Sciences at the City University of Hong Kong with concurrent appointment as a Principal Investigator at the Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet in Stockholm.

He earned his doctoral degree in medical epidemiology from Karolinska Institutet in 2011 and completed a postdoctoral training at Massachusetts General Hospital and Harvard Medical School in 2015. With nearly 15 years of experience in genome editing research, Prof. Zheng has pioneered the development of precision editing nucleases (SpCas9-HF, SaCas9-HF) and sensitive, unbiased off-target analysis methods (GUIDE-Seq and EDITED-Seq).

He has published over 60 scholarly publications papers in leading international medical and science journals, including New England Journal of Medicine, Nature, Nature Biotechnology, Nature Medicine, and Gastroenterology, spanning gene therapy, human genetics, molecular diagnostics and genome bioinformatics. His publications have been cited nearly 18,000 times.

Tian ZHU, PhD

Co-Founder and CEO

Dr. Zhu is a passionate novel drug hunter with nearly 15 years of industry experience in innovative drug and business developments. As a versatile professional, she excels in both scientific innovation and  business strategy, with expertise spanning R&D, intellectual property rights, investment and global partnership.

She earned her doctoral degree in Pharmaceutics and Drug Design from the University of Illinois Chicago. Before joining GenEditBio, she served as a Vice-President of Business Development at Jacobio Pharma and as a Research Investigator and Assistant to Vice-President in the R&D Department at Betta Pharmaceuticals—both are China-based pharmaceutical companies. Dr. Zhu is a sought-after speaker at national and international biotechnology, healthcare, and business development conferences and events.